210 related articles for article (PubMed ID: 33804620)
21. 5-ethyl-2'-deoxyuridine, a modulator of both antitumour action and pharmacokinetics of 5-fluorouracil.
Kralovánszky J; Katona C; Jeney A; Pandi E; Noordhuis P; Erdélyi-Tóth V; Otvös L; Kovács P; Van der Wilt CL; Peters GJ
J Cancer Res Clin Oncol; 1999 Dec; 125(12):675-84. PubMed ID: 10592100
[TBL] [Abstract][Full Text] [Related]
22. Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil.
de Angelis PM; Fjell B; Kravik KL; Haug T; Tunheim SH; Reichelt W; Beigi M; Clausen OP; Galteland E; Stokke T
Int J Oncol; 2004 May; 24(5):1279-88. PubMed ID: 15067352
[TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo evaluation of novel antitumor prodrugs of 5-fluoro-2'-deoxyuridine activated by hypoxic irradiation.
Shibamoto Y; Tachi Y; Tanabe K; Hatta H; Nishimoto S
Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):397-402. PubMed ID: 14751508
[TBL] [Abstract][Full Text] [Related]
24. The effects of 5-fluoropyrimidines on nascent DNA synthesis in Chinese hamster ovary cells monitored by pH-step alkaline and neutral elution.
Jones S; Willmore E; Durkacz BW
Carcinogenesis; 1994 Nov; 15(11):2435-8. PubMed ID: 7955087
[TBL] [Abstract][Full Text] [Related]
25. Properties of Parallel Tetramolecular G-Quadruplex Carrying
Clua A; Grijalvo S; Erande N; Gupta S; Yucius K; Gargallo R; Mazzini S; Manoharan M; Eritja R
Molecules; 2022 Jun; 27(12):. PubMed ID: 35745067
[TBL] [Abstract][Full Text] [Related]
26. Combination of 5-fluorouracil and genistein induces apoptosis synergistically in chemo-resistant cancer cells through the modulation of AMPK and COX-2 signaling pathways.
Hwang JT; Ha J; Park OJ
Biochem Biophys Res Commun; 2005 Jul; 332(2):433-40. PubMed ID: 15896711
[TBL] [Abstract][Full Text] [Related]
27. Studies directed toward the asialoglycoprotein receptor mediated delivery of 5-fluoro-2'-deoxyuridine for hepatocellular carcinoma.
Rico L; Østergaard ME; Bell M; Seth PP; Hanessian S
Bioorg Med Chem Lett; 2018 Aug; 28(15):2652-2654. PubMed ID: 30042045
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms for 5-fluorouracil resistance in human colon cancer DLD-1 cells.
Inaba M; Naoe Y; Mitsuhashi J
Biol Pharm Bull; 1998 Jun; 21(6):569-73. PubMed ID: 9657039
[TBL] [Abstract][Full Text] [Related]
29. In vitro and in vivo reversal of resistance to 5-fluorouracil in colorectal cancer cells with a novel stealth double-liposomal formulation.
Fanciullino R; Giacometti S; Mercier C; Aubert C; Blanquicett C; Piccerelle P; Ciccolini J
Br J Cancer; 2007 Oct; 97(7):919-26. PubMed ID: 17848948
[TBL] [Abstract][Full Text] [Related]
30. Effect of Foslip® mediated photodynamic therapy on 5-fluorouracil resistant human colorectal cancer cells.
Wu R; Yow C; Law E; Chu E; Huang Z
Photodiagnosis Photodyn Ther; 2020 Sep; 31():101945. PubMed ID: 32768589
[TBL] [Abstract][Full Text] [Related]
31. Comparison of 5-fluorouracil and 5-fluoro-2'-deoxyuridine as an effector in radiation-activated prodrugs.
Shibamoto Y; Mimasu Y; Tachi Y; Hatta H; Nishimoto S
J Chemother; 2002 Aug; 14(4):390-6. PubMed ID: 12420858
[TBL] [Abstract][Full Text] [Related]
32. Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil.
Mizutani Y; Nakanishi H; Yoshida O; Fukushima M; Bonavida B; Miki T
Eur J Cancer; 2002 Jan; 38(1):167-76. PubMed ID: 11750847
[TBL] [Abstract][Full Text] [Related]
33. 4-(1H-imidazo[4,5-f]-1,10-phenanthrolin-2-yl)phenol-based G-quadruplex DNA binding agents: telomerase inhibition, cytotoxicity and DNA-binding studies.
Wei CY; Wang JH; Wen Y; Liu J; Wang LH
Bioorg Med Chem; 2013 Jun; 21(11):3379-87. PubMed ID: 23611765
[TBL] [Abstract][Full Text] [Related]
34. Recent Advances in Designing 5-Fluorouracil Delivery Systems: A Stepping Stone in the Safe Treatment of Colorectal Cancer.
Entezar-Almahdi E; Mohammadi-Samani S; Tayebi L; Farjadian F
Int J Nanomedicine; 2020; 15():5445-5458. PubMed ID: 32801699
[TBL] [Abstract][Full Text] [Related]
35. G-quadruplexes: targets and tools in anticancer drug design.
Düchler M
J Drug Target; 2012 Jun; 20(5):389-400. PubMed ID: 22424091
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of resistance to fluoropyrimidines.
Zhang ZG; Harstrick A; Rustum YM
Semin Oncol; 1992 Apr; 19(2 Suppl 3):4-9. PubMed ID: 1532673
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and biological activity of 5-(2,2-difluorocyclopropyl)-2'-deoxyuridine deoxyuridine diastereomers.
Tandon M; Singh S; Xu L; Kumar P; Wiebe LI; Knaus EE; Gati WP; Tempest ML
Drug Des Discov; 1992; 9(1):79-91. PubMed ID: 1333829
[TBL] [Abstract][Full Text] [Related]
38. Potentiation of the antitumor action of 5-fluorouracil with 5-ethyl-2'-deoxyuridine in human colorectal tumor xenografts.
Kopper L; Magyarosy E; Jeney A; Lapis K; Szabolcs A; Otvös L
Oncology; 1984; 41(3):155-8. PubMed ID: 6328393
[TBL] [Abstract][Full Text] [Related]
39. Modulation of 5-fluorouracil by 5-ethyl-2'-deoxyuridine on cell lines expressing different dihydropyrimidine dehydrogenase activities.
Katona C; Tímár F; Jeney A; Fischel JL; Milano G; Pandi E; Kralovánszky J
Anticancer Drugs; 1999 Jul; 10(6):561-7. PubMed ID: 10885904
[TBL] [Abstract][Full Text] [Related]
40. The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites.
Pratt S; Shepard RL; Kandasamy RA; Johnston PA; Perry W; Dantzig AH
Mol Cancer Ther; 2005 May; 4(5):855-63. PubMed ID: 15897250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
